Astrana Health (ASTH) Financials

$24.97 +0.68 (+2.80%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$25.00 +0.03 (+0.10%)

As of 05/27/2025 04:34 PM Eastern

Annual Income Statements for Astrana Health

This table shows Astrana Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	3/31/2015	1/31/2014
Net Income / (Loss) Attributable to Common Shareholders	43	61	45	69	38	14	11	26	11	-1.80	-4.56
Consolidated Net Income / (Loss)	50	58	46	46	122	18	60	46	10	-1.35	-4.56
Net Income / (Loss) Continuing Operations	50	58	46	46	122	18	60	46	10	-1.35	-4.56
Total Pre-Tax Income	81	90	87	78	178	26	83	50	19	-1.18	-4.54
Total Operating Income	89	85	104	98	81	32	88	35	12	-0.69	-3.91
Total Gross Profit	271	215	199	178	148	94	155	83	51	11	1.41
Total Revenue	2,035	1,387	1,144	774	687	561	520	356	306	33	10
Operating Revenue	2,035	1,387	1,144	774	687	561	520	356	282	33	10
Total Cost of Revenue	1,763	1,172	945	596	539	466	365	273	255	22	9.08
Operating Cost of Revenue	1,763	1,172	945	596	539	468	361	273	255	22	9.08
Total Operating Expenses	182	130	95	80	67	62	66	48	39	12	5.32
Selling, General & Admin Expense	154	113	78	62	49	41	43	26	21	11	5.29
Depreciation Expense	28	18	18	18	18	18	19	19	18	0.33	0.03
Total Other Income / (Expense), net	-8.53	5.23	-18	-20	98	-6.58	-5.81	15	7.15	-0.49	-0.63
Interest Expense	33	16	7.92	5.39	9.50	4.73	0.56	0.08	0.06	1.33	0.68
Interest & Investment Income	19	20	7.60	-0.54	106	-4.88	-6.87	14	5.25	-	-
Other Income / (Expense), net	5.61	1.54	-17	-14	1.08	3.03	1.62	1.05	1.96	0.84	0.05
Income Tax Expense	31	32	41	32	56	8.17	22	3.89	8.82	0.16	0.02
Net Income / (Loss) Attributable to Noncontrolling Interest	6.78	-2.87	0.57	-23	84	3.56	49	20	-1.43	0.45	-
Basic Earnings per Share	$0.91	$1.30	$1.00	$1.57	$1.03	$0.41	$0.33	$1.01	$0.46	($0.37)	($0.12)
Weighted Average Basic Shares Outstanding	56.25M	55.42M	57.44M	55.96M	54.59M	52.80M	32.89M	25.53M	24.67M	4.89M	49.13M
Diluted Earnings per Share	$0.90	$1.29	$0.99	$1.52	$1.01	$0.39	$0.29	$0.90	$0.41	($0.37)	($0.12)
Weighted Average Diluted Shares Outstanding	56.25M	55.42M	57.44M	55.96M	54.59M	52.80M	37.91M	28.66M	27.97M	4.89M	49.13M
Weighted Average Basic & Diluted Shares Outstanding	56.25M	55.42M	57.44M	55.96M	54.59M	52.80M	32.80M	6.95M	5.21M	4.89M	36.66M

This table shows Astrana Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	16	19	15	22	13	13	-3.73	23
Consolidated Net Income / (Loss)	19	22	17	28	17	12	-0.88	24
Net Income / (Loss) Continuing Operations	19	22	17	28	17	12	-0.88	24
Total Pre-Tax Income	27	32	24	38	31	19	10	41
Total Operating Income	28	30	30	39	27	22	13	50
Total Gross Profit	73	73	74	73	55	48	41	76
Total Revenue	479	486	404	348	348	337	294	317
Operating Revenue	479	486	404	348	348	337	294	317
Total Cost of Revenue	405	413	330	275	293	289	253	241
Operating Cost of Revenue	405	413	330	275	293	289	253	241
Total Operating Expenses	45	43	44	34	28	25	29	26
Selling, General & Admin Expense	38	36	39	29	24	21	24	21
Depreciation Expense	7.26	7.44	5.10	4.31	4.25	4.29	4.06	4.75
Total Other Income / (Expense), net	-1.61	1.83	-6.14	-1.07	4.46	-2.96	-2.13	-8.83
Interest Expense	8.86	8.59	7.59	3.78	3.63	3.27	2.57	2.42
Interest & Investment Income	5.13	4.42	4.63	1.18	6.05	5.49	2.51	1.68
Other Income / (Expense), net	2.11	6.00	-3.18	1.53	2.04	-5.19	-2.07	-8.08
Income Tax Expense	7.83	10	7.14	10	14	6.92	11	17
Net Income / (Loss) Attributable to Noncontrolling Interest	2.89	2.70	2.03	5.91	4.31	-0.64	2.85	0.71
Basic Earnings per Share	$0.34	$0.40	$0.31	$0.47	$0.28	$0.28	($0.10)	$0.52
Weighted Average Basic Shares Outstanding	56.25M	56.21M	56.03M	58.28M	57.56M	57.55M	57.44M	44.95M
Diluted Earnings per Share	$0.33	$0.40	$0.31	$0.47	$0.28	$0.28	($0.07)	$0.50
Weighted Average Diluted Shares Outstanding	56.25M	56.21M	56.03M	58.28M	57.56M	57.55M	57.44M	46.15M
Weighted Average Basic & Diluted Shares Outstanding	56.25M	56.21M	56.03M	58.28M	57.56M	57.55M	57.44M	56.72M

This table details how cash moves in and out of Astrana Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	3/31/2015	1/31/2014
Net Change in Cash & Equivalents	-5.05	6.13	55	39	90	-3.63	-11	64	-4.19	-1.82	0.27
Net Cash From Operating Activities	52	68	82	70	46	14	25	52	22	-0.27	-1.48
Net Cash From Continuing Operating Activities	52	68	82	70	46	14	25	52	22	-0.27	-1.48
Net Income / (Loss) Continuing Operations	50	58	46	46	122	18	60	46	10	-1.35	-4.56
Consolidated Net Income / (Loss)	50	58	46	46	122	18	60	46	10	-1.35	-4.56
Depreciation Expense	28	18	18	18	18	18	19	19	18	0.33	0.03
Amortization Expense	1.83	1.06	0.94	1.08	1.35	0.47	0.00	-	-	0.52	0.39
Non-Cash Adjustments To Reconcile Net Income	37	28	38	31	-100	9.31	-4.18	-6.49	0.99	0.50	2.14
Changes in Operating Assets and Liabilities, net	-64	-36	-20	-25	4.08	-32	-50	-6.57	-7.21	-0.28	0.52
Net Cash From Investing Activities	-192	-66	-7.11	17	95	-181	-25	27	-8.96	-3.20	-0.27
Net Cash From Continuing Investing Activities	-192	-66	-7.11	17	95	-181	-25	27	-8.96	-3.20	-0.27
Purchase of Property, Plant & Equipment	-8.03	-29	-23	-19	-1.16	-1.04	-1.17	-2.08	-3.31	-0.04	-0.02
Acquisitions	-152	-6.84	-16	-16	-21	-53	-17	0.00	-2.44	-3.36	-0.25
Purchase of Investments	-6.52	-6.15	-1.85	-28	-1.94	-127	-7.91	-10	-5.21	-	-
Sale and/or Maturity of Investments	0.12	0.49	32	68	67	0.24	0.61	1.44	2.00	0.44	-
Other Investing Activities, net	-26	-24	1.96	5.93	0.00	0.00	-	0.23	0.00	-0.24	-
Net Cash From Financing Activities	135	3.42	-20	-48	-52	163	-11	-15	-17	1.66	2.03
Net Cash From Continuing Financing Activities	135	3.42	-20	-48	-52	163	-11	-15	-17	1.66	2.03
Repayment of Debt	-19	-205	-4.43	-239	-9.61	-55	-0.59	-9.10	-2.26	-1.47	-1.50
Repurchase of Common Equity	-0.94	-14	-9.25	-6.47	-0.54	-13	-5.05	-3.18	-0.52	-	-
Payment of Dividends	-3.93	-62	-19	-33	-52	-62	-18	-10	-26	-0.60	-0.24
Issuance of Debt	172	285	3.60	181	0.00	290	8.00	5.00	0.00	3.00	3.03
Issuance of Common Equity	0.27	0.00	0.00	40	0.00	0.00	0.20	2.16	11	0.73	0.73
Other Financing Activities, net	-13	0.52	8.63	9.06	11	3.12	4.00	0.59	0.26	-0.00	0.00
Cash Interest Paid	30	14	6.67	4.16	8.51	4.26	0.46	0.05	0.06	0.77	0.25
Cash Income Taxes Paid	44	57	47	37	62	20	24	24	29	0.03	0.02

This table details how cash moves in and out of Astrana Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2024	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	41	-20	20	-13	104	-50
Net Cash From Operating Activities	5.98	15	26	7.72	85	-36
Net Cash From Continuing Operating Activities	5.98	15	26	7.72	85	-36
Net Income / (Loss) Continuing Operations	17	28	17	12	-0.88	24
Consolidated Net Income / (Loss)	17	28	17	12	-0.88	24
Depreciation Expense	5.10	4.31	4.25	4.29	4.06	4.76
Amortization Expense	0.46	0.24	0.24	0.24	0.24	0.23
Non-Cash Adjustments To Reconcile Net Income	4.09	5.98	4.46	8.73	8.93	12
Changes in Operating Assets and Liabilities, net	-21	-23	-0.63	-18	73	-76
Net Cash From Investing Activities	-71	-35	-5.19	-14	13	-8.09
Net Cash From Continuing Investing Activities	-71	-35	-5.19	-14	13	-8.09
Purchase of Property, Plant & Equipment	-0.37	-4.11	-11	-6.03	-0.89	-3.21
Acquisitions	-51	-5.02	0.35	-0.33	-11	-4.76
Purchase of Investments	-20	-25	-3.02	-1.00	-0.10	-
Sale and/or Maturity of Investments	0.01	0.06	0.00	2.14	25	-0.02
Other Investing Activities, net	0.00	-0.70	8.82	-8.82	-0.32	-0.10
Net Cash From Financing Activities	106	-0.51	-0.96	-7.10	5.87	-6.25
Net Cash From Continuing Financing Activities	106	-0.51	-0.96	-7.10	5.87	-6.25
Repayment of Debt	-3.68	-0.35	-0.31	-0.31	-0.30	-3.65
Repurchase of Common Equity	0.00	-0.15	-	-9.54	0.40	-0.17
Payment of Dividends	0.03	-1.42	-0.72	-0.12	-6.03	-0.09
Issuance of Debt	110	1.42	0.12	1.62	1.61	0.75
Other Financing Activities, net	0.00	-	-0.05	1.25	10	-3.09
Cash Interest Paid	6.43	3.41	3.27	2.99	2.29	2.16
Cash Income Taxes Paid	0.19	-	-	0.00	5.50	20

This table presents Astrana Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	3/31/2015	3/31/2014
Total Assets	1,355	933	966	867	817	729	513	491	350	15	9.48
Total Current Assets	638	462	428	404	339	329	173	144	81	9.85	8.43
Cash & Equivalents	288	294	288	233	193	103	107	100	55	5.01	6.83
Short-Term Investments	2.38	2.50	5.57	53	68	117	1.13	1.14	1.05	-	-
Accounts Receivable	305	137	117	90	61	76	57	20	22	4.05	1.53
Prepaid Expenses	23	17	15	19	17	10	7.39	5.14	1.85	0.79	0.04
Current Deferred & Refundable Income Taxes	19	11	0.00	-	-	-	-	-	-	-	-
Plant, Property, & Equipment, net	14	7.17	109	53	30	12	13	14	10	0.58	0.09
Total Noncurrent Assets	702	465	430	410	449	388	327	333	258	4.56	0.96
Long-Term Investments	48	32	43	43	80	29	35	22	35	-	-
Noncurrent Note & Lease Receivables	51	26	0.00	0.57	4.63	0.00	18	15	5.20	-	-
Goodwill	419	279	269	246	239	239	186	190	103	2.17	0.49
Intangible Assets	118	72	77	83	87	103	87	104	108	1.38	0.06
Noncurrent Deferred & Refundable Income Taxes	16	16	16	16	-	-	-	-	-	-	-
Other Noncurrent Operating Assets	49	40	25	21	38	17	1.95	2.38	6.94	0.75	0.04
Total Liabilities & Shareholders' Equity	1,355	933	966	867	817	729	513	491	350	15	9.48
Total Liabilities	841	523	408	357	372	368	106	154	100	16	11
Total Current Liabilities	366	219	149	115	115	105	72	110	51	5.97	2.44
Short-Term Debt	9.38	20	0.62	0.78	11	9.50	0.04	0.61	0.10	1.04	-
Accounts Payable	114	68	58	54	46	29	27	20	9.13	3.34	1.45
Dividends Payable	0.64	0.64	0.66	0.56	0.49	0.27	0.00	-	-	-	-
Other Current Liabilities	241	131	85	59	54	62	34	85	39	1.59	1.00
Total Noncurrent Liabilities	475	304	259	242	257	262	34	45	49	10	8.66
Long-Term Debt	425	259	203	183	230	232	0.00	-	-	7.69	6.31
Noncurrent Deferred & Payable Income Tax Liabilities	4.56	4.07	14	30	11	18	20	25	47	0.17	0.00
Other Noncurrent Operating Liabilities	45	41	41	29	16	12	1.19	19	2.00	2.14	2.35
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-203	-206	14	57	114	169	225	172	163	0.00	-
Total Equity & Noncontrolling Interests	717	617	544	454	331	192	182	164	88	-0.99	-1.62
Total Preferred & Common Equity	713	614	543	448	331	192	181	160	87	-2.82	-1.22
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	713	614	543	448	331	192	181	160	87	-2.82	-1.22
Common Stock	426	371	360	311	261	160	163	158	88	17	15
Retained Earnings	286	243	182	137	70	32	18	1.73	-0.77	-19	-16
Noncontrolling Interest	4.01	2.43	1.75	5.94	0.09	0.79	1.00	4.24	0.38	1.83	-0.41

This table presents Astrana Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,285	1,252	1,226	1,073	1,027	999	943
Total Current Assets	597	570	539	476	465	455	444
Cash & Equivalents	348	325	335	274	294	275	184
Short-Term Investments	2.35	2.38	2.49	3.02	3.79	4.11	33
Accounts Receivable	210	203	184	184	151	153	202
Prepaid Expenses	21	17	17	14	15	22	12
Current Deferred & Refundable Income Taxes	16	22	0.00	-	-	0.00	12
Plant, Property, & Equipment, net	12	10	7.99	129	124	113	104
Total Noncurrent Assets	676	672	679	468	438	431	396
Long-Term Investments	44	42	42	47	49	44	40
Noncurrent Note & Lease Receivables	55	49	47	25	-	-	2.64
Goodwill	410	410	410	276	274	269	257
Intangible Assets	109	116	120	74	74	78	73
Noncurrent Deferred & Refundable Income Taxes	16	16	16	16	16	16	-
Other Noncurrent Operating Assets	43	39	44	30	25	24	22
Total Liabilities & Shareholders' Equity	1,285	1,252	1,226	1,073	1,027	999	943
Total Liabilities	778	774	774	458	444	434	390
Total Current Liabilities	313	310	355	203	186	173	156
Short-Term Debt	15	17	21	2.99	2.63	0.62	3.16
Accounts Payable	101	103	154	59	59	58	54
Dividends Payable	0.64	0.64	0.64	0.64	0.64	0.66	0.56
Other Current Liabilities	196	189	174	110	104	102	99
Total Noncurrent Liabilities	465	464	419	255	258	260	234
Long-Term Debt	423	425	368	206	205	205	199
Noncurrent Deferred & Payable Income Tax Liabilities	2.86	3.25	3.76	12	12	14	4.70
Other Noncurrent Operating Liabilities	39	36	45	36	39	40	30
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-203	-204	-206	18	14	14	40
Total Equity & Noncontrolling Interests	710	683	658	598	570	551	514
Total Preferred & Common Equity	705	679	653	594	566	548	510
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	705	679	653	594	566	548	510
Common Stock	411	402	396	363	357	353	315
Retained Earnings	293	277	258	231	209	196	195
Noncontrolling Interest	5.00	4.13	4.49	4.00	3.74	2.71	3.07

This table displays calculated financial ratios and metrics derived from Astrana Health's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	3/31/2015	1/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	46.72%	21.19%	47.84%	12.62%	22.58%	7.83%	45.90%	16.48%	827.36%	214.66%	34.83%
EBITDA Growth	18.82%	-0.43%	3.07%	0.99%	86.85%	-50.43%	97.87%	74.02%	3,080.20%	129.06%	52.19%
EBIT Growth	10.22%	-0.90%	3.89%	2.58%	130.13%	-60.63%	148.83%	32.62%	19,084.99%	103.68%	51.56%
NOPAT Growth	1.32%	-1.05%	-5.32%	5.58%	148.41%	-65.62%	99.09%	421.06%	1,379.27%	82.24%	-88.11%
Net Income Growth	-13.69%	26.47%	-0.68%	-62.28%	590.79%	-70.68%	31.52%	357.34%	843.33%	70.43%	48.80%
EPS Growth	-30.23%	30.30%	-34.87%	50.50%	158.97%	34.48%	-67.78%	119.51%	421.62%	-208.33%	55.56%
Operating Cash Flow Growth	-23.49%	-16.93%	16.77%	52.36%	237.62%	-46.37%	-50.81%	136.54%	16,318.40%	81.61%	-2,650.56%
Free Cash Flow Firm Growth	-261.49%	1,119.33%	-127.22%	-32.14%	216.38%	-249.46%	-110.11%	152.04%	-5,571.54%	-6,701.33%	90.63%
Invested Capital Growth	68.92%	-15.36%	18.56%	4.31%	-2.45%	27.79%	40.75%	-38.42%	12,784.07%	197.12%	-2,160.19%
Revenue Q/Q Growth	0.00%	4.43%	9.48%	2.42%	-0.29%	14.77%	2.77%	-33.70%	631.54%	27.29%	8.25%
EBITDA Q/Q Growth	0.00%	-8.92%	42.07%	-31.27%	16.09%	19.56%	7.04%	-38.61%	1,396.82%	352.89%	-29.17%
EBIT Q/Q Growth	0.00%	-11.54%	56.84%	-35.68%	21.27%	31.01%	8.93%	-37.38%	1,058.05%	-93.55%	-22.94%
NOPAT Q/Q Growth	0.00%	-6.12%	30.81%	-26.57%	19.67%	24.94%	-9.62%	-4.87%	282.58%	50.51%	-20.94%
Net Income Q/Q Growth	0.00%	1.38%	89.99%	-43.33%	12.90%	3.89%	-27.49%	17.53%	347.88%	34.04%	-13.70%
EPS Q/Q Growth	0.00%	34.38%	-21.43%	-3.80%	6.32%	254.55%	-65.88%	-48.86%	147.13%	17.78%	-9.09%
Operating Cash Flow Q/Q Growth	0.00%	-49.03%	647.48%	-12.00%	-11.82%	267.94%	-46.19%	-13.70%	896.00%	-1,054.20%	-39.80%
Free Cash Flow Firm Q/Q Growth	0.00%	114.81%	90.25%	-26.13%	-14.58%	-7.00%	92.23%	494.16%	-27,207.32%	-331.51%	96.30%
Invested Capital Q/Q Growth	0.00%	-27.90%	-14.45%	7.13%	9.41%	2.84%	0.64%	9,253.81%	5,565.79%	171.63%	-2,850.14%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	13.34%	15.50%	17.43%	22.97%	21.53%	16.80%	29.79%	23.26%	39.53%	33.11%	13.43%
EBITDA Margin	6.13%	7.57%	9.21%	13.22%	14.74%	9.67%	21.03%	15.51%	20.76%	3.03%	-32.78%
Operating Margin	4.39%	6.10%	9.11%	12.69%	11.72%	5.78%	17.01%	9.86%	7.64%	-2.10%	-37.29%
EBIT Margin	4.67%	6.21%	7.60%	10.81%	11.87%	6.32%	17.32%	10.16%	8.92%	0.43%	-36.82%
Profit (Net Income) Margin	2.45%	4.17%	4.00%	5.95%	17.77%	3.15%	11.59%	12.86%	6.55%	-4.09%	-43.48%
Tax Burden Percent	61.78%	64.39%	52.81%	59.24%	68.42%	68.39%	72.94%	92.18%	152.33%	113.83%	100.43%
Interest Burden Percent	85.11%	104.28%	99.63%	92.91%	218.71%	72.89%	91.75%	137.36%	276.10%	-832.50%	117.59%
Effective Tax Rate	38.22%	35.61%	47.19%	40.76%	31.58%	31.61%	27.06%	7.82%	46.81%	0.00%	0.00%
Return on Invested Capital (ROIC)	11.36%	13.82%	13.99%	16.49%	15.76%	7.03%	27.24%	12.55%	7.67%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-11.13%	10.11%	20.60%	26.15%	-109.33%	13.60%	30.38%	1.34%	-1.05%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-0.56%	-1.89%	-5.44%	-6.85%	14.53%	-2.43%	-11.01%	-0.54%	0.37%	0.00%	0.00%
Return on Equity (ROE)	10.80%	11.94%	8.56%	9.64%	30.29%	4.60%	16.22%	12.01%	8.03%	103.16%	452.60%
Cash Return on Invested Capital (CROIC)	-39.90%	30.46%	-2.99%	12.27%	18.24%	-17.37%	-6.62%	60.10%	-383.23%	-222.71%	0.00%
Operating Return on Assets (OROA)	8.30%	9.07%	9.48%	9.93%	10.55%	5.71%	17.95%	8.61%	14.95%	1.16%	-60.76%
Return on Assets (ROA)	4.36%	6.09%	4.99%	5.47%	15.79%	2.85%	12.01%	10.90%	10.98%	-11.01%	-71.76%
Return on Common Equity (ROCE)	15.49%	14.24%	7.93%	7.85%	19.62%	2.23%	7.43%	5.06%	55,787.31%	159.19%	352.72%
Return on Equity Simple (ROE_SIMPLE)	7.01%	9.42%	8.43%	10.28%	36.90%	9.23%	33.38%	28.65%	11.49%	47.84%	375.19%
Net Operating Profit after Tax (NOPAT)	55	54	55	58	55	22	65	32	6.22	-0.49	-2.74
NOPAT Margin	2.71%	3.93%	4.81%	7.51%	8.02%	3.96%	12.41%	9.09%	4.06%	-1.47%	-26.10%
Net Nonoperating Expense Percent (NNEP)	22.50%	3.72%	-6.61%	-9.66%	125.08%	-6.57%	-3.14%	11.22%	446.82%	67.86%	-920.47%
Return On Investment Capital (ROIC_SIMPLE)	4.79%	6.09%	7.36%	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	86.66%	84.50%	82.57%	77.03%	78.47%	83.20%	70.21%	76.74%	166.55%	66.89%	86.57%
SG&A Expenses to Revenue	7.57%	8.12%	6.79%	8.02%	7.15%	7.40%	8.34%	7.37%	45.38%	34.20%	50.42%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	8.95%	9.40%	8.32%	10.28%	9.82%	11.02%	12.78%	13.40%	52.21%	35.21%	50.72%
Earnings before Interest and Taxes (EBIT)	95	86	87	84	82	35	90	36	27	0.14	-3.86
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	125	105	105	102	101	54	109	55	32	1.00	-3.44
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	3.01	5.08	4.17	4.30	0.21	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	208.37	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	1.45	1.73	1.45	1.93	0.06	0.10	2.81
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	26.46	68.87	69.46	26.66	1.59	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	3.78%	1.45%	1.44%	3.75%	63.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	2.93	3.21	3.02	3.68	0.57	3.55	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	1.47	2.02	1.61	2.03	0.59	0.26	2.72
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	9.98	20.92	7.64	13.11	2.86	8.73	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	12.39	31.99	9.28	20.02	6.65	61.32	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	18.36	51.15	12.96	22.37	14.59	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	21.90	82.95	32.79	13.98	4.14	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	15.86	0.00	0.00	4.67	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.85	0.68	0.37	0.36	0.54	0.67	0.00	0.00	0.13	-8.82	-3.89
Long-Term Debt to Equity	0.83	0.63	0.36	0.36	0.52	0.64	0.00	0.00	0.00	-7.77	-3.89
Financial Leverage	0.05	-0.19	-0.26	-0.26	-0.13	-0.18	-0.36	-0.41	-0.70	-0.97	0.20
Leverage Ratio	2.47	1.96	1.71	1.76	1.92	1.62	1.35	1.43	72.97	-9.37	-6.31
Compound Leverage Factor	2.11	2.04	1.71	1.64	4.19	1.18	1.24	1.97	81.30	77.98	-7.42
Debt to Total Capital	45.81%	40.40%	26.75%	26.46%	35.13%	40.10%	0.14%	0.36%	11.40%	112.79%	134.65%
Short-Term Debt to Total Capital	0.99%	2.83%	0.08%	0.11%	1.59%	1.58%	0.01%	0.18%	0.04%	13.41%	0.00%
Long-Term Debt to Total Capital	44.82%	37.57%	26.67%	26.34%	33.55%	38.52%	0.13%	0.18%	0.00%	99.38%	134.65%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	233.70%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-20.93%	-29.52%	2.10%	9.00%	16.66%	28.12%	55.53%	52.25%	230.16%	23.61%	-8.71%
Common Equity to Total Capital	75.11%	89.12%	71.15%	64.55%	48.21%	31.78%	44.34%	47.39%	69.61%	-36.41%	-25.94%
Debt to EBITDA	3.49	2.65	1.94	1.80	2.38	4.46	0.01	0.02	0.00	8.74	-1.84
Net Debt to EBITDA	0.77	-0.48	-1.25	-1.42	-0.99	-0.14	-1.31	-2.53	-0.27	3.72	0.16
Long-Term Debt to EBITDA	3.41	2.47	1.93	1.79	2.27	4.28	0.00	0.01	0.00	7.70	-1.84
Debt to NOPAT	7.87	5.11	3.71	3.16	4.38	10.90	0.01	0.04	0.03	-17.96	-2.30
Net Debt to NOPAT	1.73	-0.92	-2.40	-2.50	-1.82	-0.34	-2.21	-4.31	-11.02	-7.64	0.20
Long-Term Debt to NOPAT	7.70	4.75	3.69	3.15	4.18	10.47	0.01	0.02	0.00	-15.83	-2.30
Altman Z-Score	0.00	0.00	0.00	0.00	3.22	2.95	6.12	3.73	1.21	0.86	-0.30
Noncontrolling Interest Sharing Ratio	-43.46%	-19.34%	7.34%	18.50%	35.21%	51.53%	54.17%	57.88%	1,815.55%	-54.31%	22.07%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.75	2.11	2.88	3.53	2.94	3.12	2.40	1.32	5.25	1.65	3.45
Quick Ratio	1.63	1.98	2.78	3.31	2.80	3.02	2.30	1.10	3.33	1.52	3.42
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-194	120	-12	43	64	-55	-16	155	-298	-5.48	-0.08
Operating Cash Flow to CapEx	649.96%	239.15%	358.01%	365.89%	4,143.90%	1,312.19%	2,179.15%	2,486.31%	1,325.58%	-610.91%	-6,446.32%
Free Cash Flow to Firm to Interest Expense	-5.86	7.46	-1.49	8.02	6.71	-11.58	-27.95	1,946.72	-5,023.72	-4.13	-0.12
Operating Cash Flow to Interest Expense	1.58	4.24	10.37	13.04	4.86	2.89	45.45	650.45	711.61	-0.21	-2.18
Operating Cash Flow Less CapEx to Interest Expense	1.33	2.47	7.47	9.48	4.74	2.67	43.36	624.29	604.25	-0.24	-2.21
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.78	1.46	1.25	0.92	0.89	0.90	1.04	0.85	4.23	2.70	1.65
Accounts Receivable Turnover	9.19	10.93	11.10	10.30	10.06	8.40	13.40	16.81	46.49	11.83	6.72
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	189.74	23.97	14.15	18.63	32.71	45.12	39.19	29.47	111.70	97.40	128.57
Accounts Payable Turnover	19.37	18.70	16.85	11.89	14.36	16.68	15.55	18.57	81.69	9.22	7.57
Days Sales Outstanding (DSO)	39.70	33.39	32.90	35.43	36.29	43.45	27.23	21.71	49.02	30.86	54.32
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	18.84	19.52	21.66	30.70	25.42	21.88	23.47	19.66	51.41	39.59	48.21
Cash Conversion Cycle (CCC)	20.86	13.87	11.24	4.73	10.87	21.57	3.76	2.05	6.77	-8.73	6.11
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	610	361	427	360	345	354	277	197	319	2.46	-2.53
Invested Capital Turnover	4.19	3.52	2.91	2.19	1.97	1.78	2.20	1.38	7.54	-905.47	-8.70
Increase / (Decrease) in Invested Capital	249	-66	67	15	-8.68	77	80	-123	634	4.99	-2.66
Enterprise Value (EV)	0.00	0.00	0.00	0.00	1,011	1,134	836	725	91	8.72	29
Market Capitalization	0.00	0.00	0.00	0.00	997	972	753	688	36	3.18	29
Book Value per Share	$12.67	$10.54	$9.57	$8.07	$6.10	$5.49	$5.30	$26.51	$29.28	($0.06)	($0.03)
Tangible Book Value per Share	$3.12	$4.53	$3.47	$2.14	$0.09	($4.30)	($2.70)	($22.12)	($20.87)	($0.13)	($0.05)
Total Capital	949	689	763	694	686	603	407	338	501	7.74	4.68
Total Debt	435	278	204	184	241	242	0.56	1.23	0.29	8.73	6.31
Total Long-Term Debt	425	259	203	183	230	232	0.52	0.62	0.00	7.69	6.31
Net Debt	96	-50	-132	-145	-100	-7.45	-143	-140	-100	3.72	-0.54
Capital Expenditures (CapEx)	8.03	29	23	19	1.11	1.04	1.17	2.08	6.61	0.04	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-8.57	-34	-13	4.01	-27	13	-7.14	-84	-28	-0.09	-0.87
Debt-free Net Working Capital (DFNWC)	282	262	280	291	234	233	101	35	61	4.92	5.98
Net Working Capital (NWC)	273	243	280	290	224	224	101	35	61	3.89	5.98
Net Nonoperating Expense (NNE)	5.27	-3.36	9.32	12	-67	4.50	4.23	-13	-0.72	0.86	1.82
Net Nonoperating Obligations (NNO)	96	-49	-132	-151	-100	-7.18	-130	-140	-100	3.45	-0.91
Total Depreciation and Amortization (D&A)	30	19	18	19	20	19	19	19	36	0.86	0.42
Debt-free, Cash-free Net Working Capital to Revenue	-0.42%	-2.45%	-1.18%	0.52%	-3.88%	2.38%	-1.37%	-23.50%	-21.70%	-0.27%	-8.29%
Debt-free Net Working Capital to Revenue	13.87%	18.92%	24.48%	37.54%	34.12%	41.59%	19.40%	9.87%	38.69%	14.93%	57.06%
Net Working Capital to Revenue	13.41%	17.51%	24.43%	37.44%	32.54%	39.89%	19.40%	9.70%	23.89%	11.78%	57.06%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.91	$1.30	$0.00	$1.69	$1.04	$0.41	$0.33	$0.00	($1.33)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	56.25M	55.42M	0.00	55.96M	36.53M	34.71M	32.89M	0.00	30.42M	0.00	0.00
Adjusted Diluted Earnings per Share	$0.90	$1.29	$0.00	$1.63	$1.01	$0.39	$0.29	$0.00	($1.38)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	56.25M	55.42M	0.00	55.96M	37.45M	36.40M	37.91M	0.00	5.75M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	($1.79)	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	56.25M	55.42M	0.00	55.96M	54.59M	52.80M	35.80M	0.00	10.43M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	55	54	55	58	55	24	67	35	6.39	-0.49	-2.74
Normalized NOPAT Margin	2.71%	3.93%	4.81%	7.51%	8.02%	4.20%	12.94%	9.72%	4.18%	-1.47%	-26.10%
Pre Tax Income Margin	3.97%	6.48%	7.57%	10.05%	25.97%	4.61%	15.89%	13.95%	12.31%	-3.59%	-43.30%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	2.87	5.35	10.98	15.51	8.59	7.49	160.52	454.15	221.54	0.11	-5.68
NOPAT to Interest Expense	1.67	3.38	6.95	10.78	5.80	4.68	114.98	406.56	302.86	-0.37	-4.03
EBIT Less CapEx to Interest Expense	2.63	3.58	8.08	11.95	8.47	7.27	158.44	427.99	335.72	0.07	-5.72
NOPAT Less CapEx to Interest Expense	1.43	1.61	4.06	7.22	5.68	4.46	112.89	380.39	141.81	-0.40	-4.06
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	7.86%	107.44%	40.75%	70.59%	42.89%	349.06%	29.42%	22.80%	509.69%	-44.51%	-5.26%
Augmented Payout Ratio	9.74%	131.85%	60.97%	84.63%	43.33%	424.55%	37.80%	29.73%	520.02%	-44.51%	-5.26%

This table displays calculated financial ratios and metrics derived from Astrana Health's official financial filings.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	37.49%	39.65%	19.90%	9.83%	29.11%	28.10%	50.80%	39.58%
EBITDA Growth	-16.29%	29.65%	49.74%	-3.90%	58.76%	-3.38%	190.32%	2,015.78%
EBIT Growth	-24.82%	24.06%	56.89%	-3.32%	75.67%	-3.79%	150.10%	676.82%
NOPAT Growth	-30.03%	37.36%	47.08%	-0.86%	43.84%	-12.38%	-167.46%	-22.04%
Net Income Growth	-32.15%	25.08%	35.03%	17.06%	55.02%	9.07%	96.08%	543.77%
EPS Growth	-29.79%	42.86%	10.71%	-6.00%	7.69%	-6.67%	-135.00%	-32.43%
Operating Cash Flow Growth	0.00%	0.00%	-22.58%	142.95%	186.02%	-67.88%	796.79%	-170.01%
Free Cash Flow Firm Growth	-215.27%	-287.15%	116.51%	119.87%	71.22%	-96.89%	-421.18%	-907.55%
Invested Capital Growth	10.13%	23.57%	3.06%	0.43%	9.00%	15.15%	18.98%	48.47%
Revenue Q/Q Growth	-1.55%	20.26%	0.00%	-0.01%	3.25%	14.63%	-7.19%	17.54%
EBITDA Q/Q Growth	-13.12%	33.82%	0.00%	34.57%	54.55%	46.57%	-68.47%	122.32%
EBIT Q/Q Growth	-15.34%	33.78%	0.00%	39.71%	69.18%	63.42%	-74.97%	153.84%
NOPAT Q/Q Growth	-2.37%	-2.65%	0.00%	91.66%	4.24%	1,454.89%	-103.66%	178.10%
Net Income Q/Q Growth	-13.19%	29.68%	0.00%	60.01%	39.99%	1,514.27%	-103.70%	111.91%
EPS Q/Q Growth	-17.50%	29.03%	0.00%	67.86%	0.00%	500.00%	-114.00%	92.31%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	-40.30%	234.22%	-90.91%	336.80%	-497.63%
Free Cash Flow Firm Q/Q Growth	63.73%	-1,243.46%	0.00%	221.82%	51.25%	35.44%	48.17%	-76.44%
Invested Capital Q/Q Growth	0.09%	18.93%	0.00%	12.30%	-0.80%	5.02%	-14.15%	21.88%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	15.35%	15.11%	18.29%	20.91%	15.89%	14.19%	13.97%	24.05%
EBITDA Margin	7.90%	8.95%	8.04%	12.97%	9.64%	6.44%	5.04%	14.82%
Operating Margin	5.94%	6.18%	7.45%	11.23%	7.76%	6.63%	4.28%	15.80%
EBIT Margin	6.38%	7.42%	6.67%	11.67%	8.35%	5.10%	3.57%	13.25%
Profit (Net Income) Margin	3.97%	4.50%	4.17%	8.03%	5.02%	3.70%	-0.30%	7.54%
Tax Burden Percent	70.79%	68.55%	70.25%	73.58%	55.51%	64.34%	-8.44%	57.91%
Interest Burden Percent	87.80%	88.43%	89.03%	93.59%	108.32%	112.94%	99.43%	98.22%
Effective Tax Rate	29.21%	31.45%	29.75%	26.42%	44.49%	35.66%	108.44%	42.09%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	21.93%	13.06%	12.37%	-1.05%	22.90%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	22.86%	11.11%	13.86%	-1.18%	26.99%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	-3.30%	-2.54%	-3.24%	0.31%	-6.22%
Return on Equity (ROE)	0.00%	0.00%	0.00%	18.63%	10.52%	9.13%	-0.74%	16.68%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	11.17%	4.91%	-1.35%	-3.37%	-28.93%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	15.36%	10.95%	6.50%	4.46%	15.26%
Return on Assets (ROA)	0.00%	0.00%	0.00%	10.58%	6.58%	4.72%	-0.37%	8.68%
Return on Common Equity (ROCE)	0.00%	0.00%	0.00%	17.60%	9.92%	8.51%	-0.69%	14.55%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	0.00%	9.61%	9.36%	8.53%	0.00%	4.72%
Net Operating Profit after Tax (NOPAT)	20	21	21	29	15	14	-1.06	29
NOPAT Margin	4.20%	4.24%	5.24%	8.26%	4.31%	4.27%	-0.36%	9.15%
Net Nonoperating Expense Percent (NNEP)	-3.28%	3.89%	-8.28%	-0.93%	1.95%	-1.49%	0.13%	-4.09%
Cost of Revenue to Revenue	84.65%	84.89%	81.71%	79.09%	84.11%	85.81%	86.03%	75.95%
SG&A Expenses to Revenue	7.90%	7.39%	9.58%	8.45%	6.91%	6.28%	8.31%	6.75%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	9.41%	8.92%	10.84%	9.68%	8.13%	7.55%	9.69%	8.25%
Earnings before Interest and Taxes (EBIT)	31	36	27	41	29	17	11	42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	38	44	33	45	34	22	15	47
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	3.13	3.53
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	8.64	10.02
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	1.49	1.72
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	37.62	31.18
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.66%	3.21%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	3.70	3.58
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	1.39	1.71
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	15.03	24.10
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	18.23	32.26
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	28.78	42.48
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	19.30	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.86	0.92	0.86	0.34	0.36	0.37	0.37	0.37
Long-Term Debt to Equity	0.83	0.89	0.82	0.34	0.35	0.36	0.36	0.36
Financial Leverage	-0.06	-0.06	-0.10	-0.14	-0.23	-0.23	-0.26	-0.23
Leverage Ratio	2.10	2.15	2.19	1.73	1.78	1.74	1.71	1.67
Compound Leverage Factor	1.84	1.90	1.95	1.61	1.93	1.97	1.71	1.64
Debt to Total Capital	46.35%	48.01%	46.31%	25.36%	26.35%	26.78%	26.75%	26.77%
Short-Term Debt to Total Capital	1.59%	1.85%	2.46%	0.36%	0.33%	0.08%	0.08%	0.42%
Long-Term Debt to Total Capital	44.76%	46.16%	43.85%	25.00%	26.02%	26.69%	26.67%	26.36%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-20.90%	-21.74%	-23.86%	2.66%	2.22%	2.20%	2.10%	5.68%
Common Equity to Total Capital	74.54%	73.73%	77.55%	71.98%	71.43%	71.02%	71.15%	67.55%
Debt to EBITDA	0.00	0.00	0.00	1.82	1.78	1.98	1.94	2.73
Net Debt to EBITDA	0.00	0.00	0.00	-1.00	-1.18	-1.11	-1.24	-0.74
Long-Term Debt to EBITDA	0.00	0.00	0.00	1.79	1.76	1.97	1.93	2.68
Debt to NOPAT	0.00	0.00	0.00	3.60	3.61	3.86	3.71	4.81
Net Debt to NOPAT	0.00	0.00	0.00	-1.98	-2.38	-2.17	-2.38	-1.30
Long-Term Debt to NOPAT	0.00	0.00	0.00	3.55	3.56	3.85	3.69	4.73
Altman Z-Score	0.00	0.00	0.00	0.00	0.00	0.00	4.33	4.68
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	5.54%	5.72%	6.81%	7.34%	12.79%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	1.91	1.84	1.52	2.35	2.50	2.62	2.88	2.84
Quick Ratio	1.79	1.71	1.47	2.28	2.42	2.50	2.78	2.69
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-31	-85	7.40	27	-22	-45	-69	-134
Operating Cash Flow to CapEx	0.00%	0.00%	1,619.78%	375.27%	227.53%	128.09%	9,586.79%	-1,117.79%
Free Cash Flow to Firm to Interest Expense	-3.46	-9.85	0.98	7.04	-6.01	-13.71	-26.99	-55.29
Operating Cash Flow to Interest Expense	0.00	0.00	0.79	4.08	7.10	2.36	33.04	-14.81
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.74	2.99	3.98	0.52	32.69	-16.14
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	1.32	1.31	1.27	1.25	1.15
Accounts Receivable Turnover	0.00	0.00	0.00	6.87	8.29	8.18	11.10	7.45
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	11.41	12.29	13.26	14.15	13.62
Accounts Payable Turnover	0.00	0.00	0.00	19.61	17.29	17.93	16.85	14.37
Days Sales Outstanding (DSO)	0.00	0.00	0.00	53.15	44.05	44.61	32.90	48.99
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	18.61	21.11	20.35	21.66	25.41
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	34.54	22.94	24.26	11.24	23.58
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	552	551	464	501	446	450	428	499
Invested Capital Turnover	0.00	0.00	0.00	2.66	3.03	2.90	2.90	2.50
Increase / (Decrease) in Invested Capital	51	105	14	2.15	37	59	68	163
Enterprise Value (EV)	0.00	0.00	0.00	0.00	0.00	0.00	1,585	1,788
Market Capitalization	0.00	0.00	0.00	0.00	0.00	0.00	1,700	1,800
Book Value per Share	$12.53	$12.12	$11.79	$10.32	$9.84	$9.55	$9.57	$9.04
Tangible Book Value per Share	$3.31	$2.73	$2.23	$4.24	$3.78	$3.50	$3.47	$3.18
Total Capital	945	921	843	825	792	772	763	756
Total Debt	438	442	390	209	209	207	204	202
Total Long-Term Debt	423	425	369	206	206	206	203	199
Net Debt	44	72	11	-115	-138	-116	-131	-55
Capital Expenditures (CapEx)	0.00	0.00	0.37	4.11	11	6.03	0.89	3.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-51	-50	-133	-0.70	-16	3.33	-13	73
Debt-free Net Working Capital (DFNWC)	299	278	204	276	282	282	280	291
Net Working Capital (NWC)	284	261	184	273	279	281	280	287
Net Nonoperating Expense (NNE)	1.14	-1.26	4.31	0.79	-2.48	1.91	-0.18	5.11
Net Nonoperating Obligations (NNO)	45	73	11	-114	-137	-115	-130	-54
Total Depreciation and Amortization (D&A)	7.26	7.44	5.55	4.54	4.49	4.53	4.30	4.98
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	-0.05%	-1.25%	0.27%	-1.18%	7.01%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	20.81%	21.74%	23.15%	24.48%	27.81%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	20.58%	21.54%	23.10%	24.43%	27.50%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.34	$0.40	$0.31	$0.47	$0.28	$0.00	($0.10)	$0.58
Adjusted Weighted Average Basic Shares Outstanding	56.25M	56.21M	56.03M	46.55M	57.56M	0.00	57.44M	56.72M
Adjusted Diluted Earnings per Share	$0.33	$0.40	$0.31	$0.47	$0.28	$0.00	($0.07)	$0.56
Adjusted Weighted Average Diluted Shares Outstanding	56.25M	56.21M	56.03M	46.92M	57.56M	0.00	57.44M	56.72M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	56.25M	56.21M	56.03M	58.28M	57.56M	0.00	57.44M	56.72M
Normalized Net Operating Profit after Tax (NOPAT)	20	21	21	29	15	14	8.81	29
Normalized NOPAT Margin	4.20%	4.24%	5.24%	8.26%	4.31%	4.27%	2.99%	9.15%
Pre Tax Income Margin	5.60%	6.56%	5.94%	10.92%	9.04%	5.76%	3.55%	13.02%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	3.45	4.20	3.55	10.75	8.00	5.26	4.09	17.35
NOPAT to Interest Expense	2.27	2.40	2.79	7.61	4.13	4.40	-0.41	11.98
EBIT Less CapEx to Interest Expense	0.00	0.00	3.51	9.66	4.88	3.41	3.75	16.02
NOPAT Less CapEx to Interest Expense	0.00	0.00	2.74	6.52	1.01	2.56	-0.76	10.65
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	14.54%	13.14%	37.67%	40.75%	58.28%
Augmented Payout Ratio	0.00%	0.00%	0.00%	30.82%	30.71%	77.34%	60.97%	101.37%

Frequently Asked Questions About Astrana Health's Financials

When does Astrana Health's financial year end?

According to the most recent income statement we have on file, Astrana Health's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Astrana Health's net income changed over the last 10 years?

Astrana Health's net income appears to be on an upward trend, with a most recent value of $49.93 million in 2024, falling from -$4.56 million in 2014. The previous period was $57.85 million in 2023. Check out Astrana Health's forecast to explore projected trends and price targets.

What is Astrana Health's operating income?

Astrana Health's total operating income in 2024 was $89.35 million, based on the following breakdown:

Total Gross Profit: $271.39 million
Total Operating Expenses: $182.04 million

How has Astrana Health revenue changed over the last 10 years?

Over the last 10 years, Astrana Health's total revenue changed from $10.48 million in 2014 to $2.03 billion in 2024, a change of 19,305.6%.

How much debt does Astrana Health have?

Astrana Health's total liabilities were at $840.73 million at the end of 2024, a 60.9% increase from 2023, and a 7,469.7% increase since 2014.

How much cash does Astrana Health have?

In the past 10 years, Astrana Health's cash and equivalents has ranged from $5.01 million in 2015 to $293.81 million in 2023, and is currently $288.46 million as of their latest financial filing in 2024.

How has Astrana Health's book value per share changed over the last 10 years?

Over the last 10 years, Astrana Health's book value per share changed from -0.03 in 2014 to 12.67 in 2024, a change of -39,693.8%.

Related Companies

This page (NASDAQ:ASTH) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Astrana Health (ASTH) Financials

Frequently Asked Questions About Astrana Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Astrana Health (ASTH) Financials

Annual Income Statements for Astrana Health

Quarterly Income Statements for Astrana Health

Annual Cash Flow Statements for Astrana Health

Quarterly Cash Flow Statements for Astrana Health

Annual Balance Sheets for Astrana Health

Quarterly Balance Sheets for Astrana Health

Annual Metrics And Ratios for Astrana Health

Quarterly Metrics And Ratios for Astrana Health

Frequently Asked Questions About Astrana Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools